Sector News

CEO-hunting Sanofi tried to tempt AstraZeneca’s Soriot: Bloomberg

October 30, 2014
Life sciences
Bernstein analyst Tim Anderson figures Sanofi would do well to look outside the company for its new CEO, like AstraZeneca did with its new-ish chief, Pascal Soriot. Well, Sanofi had a more literal view: The French drugmaker has contacted Soriot himself.
 
Sanofi’s board sacked CEO Chris Viehbacher Wednesday, ending an 8-year tenure full of buyouts, job cuts, international expansion and R&D restructuring. Apparently, that tenure also included conflict with the board, at least in recent months. Chairman Serge Weinberg said the board wants to work more closely and cooperatively with a CEO; Weinberg has been casting about for a potential replacement since early September at least.
 
As Bloomberg reports, Sanofi’s board approached Soriot to see if he might be interested in the job. According to the news service’s sources, Soriot wasn’t.
 
Soriot joined AstraZeneca in 2012  from Roche, where he ran the Swiss drugmaker’s pharma division. He has his hands full at AstraZeneca, which has been struggling to replace revenue lost to generic competition, particularly for its antipsychotic drug Seroquel. Like Viehbacher, he has made a series of deals designed to restock the company’s pipeline and rolled out a restructuring with thousands of job cuts. Unlike Viehbacher, Soriot had to contend with a hostile bid from Pfizer, which gave up its takeover quest in May–at least temporarily.
 
That Sanofi would reach out to Soriot might soothe investors and analysts worried that Sanofi will return to its insular, France-centric ways. But then again, Soriot is French–and as Bloomberg points out, he worked at Aventis before his career at Roche. Sanofi’s previous moniker was Sanofi-Aventis, of course, which means Soriot has been in the family.
 
Another potential CEO, according to Bloomberg’s sources, is Smith & Nephew chief Olivier Bohuon, who’s also French, with stints at the France-based drugmaker Pierre Fabre, as well as U.S.-based Abbott Laboratories and U.K. drugmaker GlaxoSmithKline. Then there’s Roch Doliveux, who’s leaving the Belgian drugmaker UCB as of Jan. 1, the news service’s sources said.
 
By Tracy Staton
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”